Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $9.34
  • 50 Day Moving Average: $12.08
  • 200 Day Moving Average: $9.27
  • 52-Week Range: $4.37 - $14.34
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -14.55
  • P/E Growth: -3.89
  • Market Cap: $1.79B
  • Outstanding Shares: 192,713,000
  • Beta: 1.87
  • Net Margins: -35.00%
  • Return on Assets: -10.26%
  • Debt-to-Equity Ratio: -12.32%
  • Current Ratio: 3.05%
  • Quick Ratio: 3.04%
Additional Links:
Companies Related to Ariad Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $11.17 (19.99% upside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateFirmActionRatingPrice TargetDetails
10/25/2016JMP SecuritiesDowngradeOutperform -> Market Perform$4.37 -> $9.37View Rating Details
10/24/2016JPMorgan Chase & Co.DowngradeNeutral -> Underweight$9.97 -> $7.00View Rating Details
10/15/2016Cowen and CompanyReiterated RatingOutperform$10.00 -> $16.00View Rating Details
10/12/2016Leerink SwannReiterated RatingOutperform$20.00View Rating Details
10/4/2016SunTrust Banks Inc.Initiated CoverageBuyView Rating Details
7/29/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details
7/29/2016Barclays PLCBoost Price TargetUnderweight$8.00 -> $9.00View Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details
5/24/2016William BlairReiterated RatingBuy$10.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$7.00 -> $5.00View Rating Details
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details
12/11/2014Credit Suisse Group AGDowngradeNeutral -> Underperform$8.00 -> $6.00View Rating Details
11/6/2014Chardan CapitalReiterated RatingNeutralView Rating Details
(Data available from 10/27/2014 forward)


Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20164($0.22)($0.17)($0.20)
Q4 20164($0.20)($0.18)($0.19)
Q1 20171($0.20)($0.20)($0.20)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.91)($0.91)($0.91)
(Data provided by Zacks Investment Research)


Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 71.99%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2016Timothy P ClacksonInsiderSell19,638$9.56$187,739.28View SEC Filing  
10/3/2016Daniel M BollagVPSell47,384$13.46$637,788.64View SEC Filing  
9/28/2016Timothy P ClacksonInsiderSell8,750$13.98$122,325.00View SEC Filing  
9/22/2016Timothy P ClacksonInsiderSell20,000$13.43$268,600.00View SEC Filing  
9/15/2016Timothy P ClacksonInsiderSell59,369$11.73$696,398.37View SEC Filing  
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
News IconActive Biotech Stock News: Opko Health (OPK), Ariad Pharmaceuticals (ARIA) - The Independent Republic (NASDAQ:ARIA) - October 26 at 3:37 PM
News IconBiotech Stocks Worth a Closer Look: Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX), Ariad Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ARIA) - October 26 at 3:37 PM
News Icon2 Stocks Attracting Analyst Attention: DiamondRock Hospitality Company (NYSE:DRH), Ariad Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:ARIA) - October 26 at 3:37 PM
News IconBernie Sanders Has Got It Wrong With Ariad Pharmaceuticals Inc (NASDAQ:ARIA) - Insider Financial (NASDAQ:ARIA) - October 26 at 3:37 PM logoAriad Pharmaceuticals: How The Lawmakers Will Get This Wrong - Seeking Alpha (NASDAQ:ARIA) - October 26 at 3:37 PM logoARIAD Pharma Reports Positive Preclinical Data Of Brigatinib (NASDAQ:ARIA) - October 26 at 12:32 PM logoARIAD Pharma (ARIA) Announces Publication of Brigatinib Preclinical Data in NSCLC (NASDAQ:ARIA) - October 26 at 12:32 PM logoAriad Pharmaceuticals : Announces Publication of the Preclinical Profile of Brigatinib in the Journal Clinical Cancer Research (NASDAQ:ARIA) - October 26 at 12:32 PM logoARIAD Pharma Reports Positive Preclinical Data Of Brigatinib - Quick Facts (NASDAQ:ARIA) - October 26 at 12:32 PM logoStock Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Announces Publication ... (NASDAQ:ARIA) - October 26 at 12:32 PM logoTrending Stocks: Diplomat Pharmacy, Facebook, Ariad Pharmaceuticals, and More (NASDAQ:ARIA) - October 26 at 12:32 PM
News IconBiotech Stocks Worth Chasing: Incyte (INCY), Ariad Pharmaceuticals (ARIA) - The Independent Republic (NASDAQ:ARIA) - October 25 at 8:45 PM logoAriad Pharmaceuticals (ARIA) Stock Downgraded at JMP Securities (NASDAQ:ARIA) - October 25 at 8:45 PM
News IconSteady Stock Movements: Ariad Pharmaceuticals, Inc (NASDAQ:ARIA) - Post Registrar (NASDAQ:ARIA) - October 25 at 3:35 PM logoAriad Pharm downgraded by JMP Securities (NASDAQ:ARIA) - October 25 at 3:35 PM logoJMP Securities Downgrades Ariad, Cites Limited Near-Term Upside In Light Of Prescription Trends (NASDAQ:ARIA) - October 25 at 3:35 PM logoDrug price pressure (NASDAQ:ARIA) - October 25 at 3:35 PM logoHere's Why JPMorgan Turned Bearish on Ariad Pharmaceuticals, Inc. (ARIA) - Smarter Analyst (NASDAQ:ARIA) - October 25 at 8:25 AM
News IconBiotech Stocks Worth Chasing: Ariad Pharmaceuticals Inc. (ARIA ... - The Independent Republic (NASDAQ:ARIA) - October 24 at 3:36 PM logoAnalyst Downgrades: Time Warner Inc, Baidu Inc, and Ariad Pharmaceuticals, Inc. - Schaeffers Research (blog) (NASDAQ:ARIA) - October 24 at 3:36 PM logoTop Analyst Upgrades and Downgrades: Ariad Pharma, Comcast, ConEd, Electronic Arts, Kinder Morgan, 3M, Time ... - 24/7 Wall St. (NASDAQ:ARIA) - October 24 at 3:36 PM
News IconBiotech Stocks Worth a Closer Look: Novavax, Inc. (NASDAQ:NVAX ... - The Voice Registrar (NASDAQ:ARIA) - October 24 at 3:36 PM
News IconAriad Pharmaceuticals, Inc.(NASDAQ:ARIA) Trending - Live Trading News (NASDAQ:ARIA) - October 22 at 6:10 AM logoAriad May Not Be the Last to Feel the Bern (NASDAQ:ARIA) - October 21 at 3:35 PM logoAriad Pharmaceuticals Responds To Congressional Letter (NASDAQ:ARIA) - October 21 at 3:18 PM
News IconChesapeake Energy Corporation (NYSE:CHK) & Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Stocks in the Spotlight - Money News (NASDAQ:ARIA) - October 21 at 11:46 AM
News IconIntraday Active Biotech Stocks News: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Mast Therapeutics, Inc. (NYSEMKT ... - The Voice Registrar (NASDAQ:ARIA) - October 21 at 11:46 AM logoARIAD Pharma (ARIA) Acknowledges Receipt of Congressional Letter; Issues Commentary - (NASDAQ:ARIA) - October 20 at 9:28 PM
News IconBiotech Stocks To Put On Your Watch List: ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), Ariad Pharmaceuticals ... - The Voice Registrar (NASDAQ:ARIA) - October 20 at 9:28 PM logoAriad Pharmaceuticals, Inc. (ARIA): Options Frenzy After Bernie Sanders Letter - Schaeffers Research (blog) (NASDAQ:ARIA) - October 20 at 9:28 PM logoWashington's next biotech target? (NASDAQ:ARIA) - October 20 at 9:28 PM
News IconIs there Upside to ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Stock? - Recall News (NASDAQ:ARIA) - October 20 at 4:00 PM
News IconFinancial Review of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - The Newburgh Press (NASDAQ:ARIA) - October 20 at 4:00 PM
News IconTwo Biotech Stocks Are Just So Hot Right Now: Ariad Pharmaceuticals Inc. (ARIA), Novavax, Inc. (NVAX) - The Independent Republic (NASDAQ:ARIA) - October 20 at 4:00 PM
News IconActive Runners Buzz: Denbury Resources Inc. (NYSE:DNR), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - NYSE Journal (press release) (NASDAQ:ARIA) - October 20 at 9:26 AM
News IconAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) Laid Low by A Tweet (NASDAQ:ARIA) - October 18 at 3:34 PM logoStocks in the Spotlight: Ariad Pharmaceuticals Inc. (ARIA), Intel Corporation (INTC), RSP Permian, Inc. (RSPP) - iStreetWire (NASDAQ:ARIA) - October 17 at 3:32 PM
News IconInsiders are Scaling Back Holdings in Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - CSZ News (NASDAQ:ARIA) - October 17 at 3:32 PM
News IconSell-side Consensus Sees ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Going Where Near-Term? - CSZ News (NASDAQ:ARIA) - October 17 at 3:32 PM
News IconAriad Pharmaceuticals, Inc. (NASDAQ:ARIA) Laid Low by A Tweet - Scibility Media (NASDAQ:ARIA) - October 17 at 3:32 PM logoCalifornia's drug pricing bill (NASDAQ:ARIA) - October 17 at 3:32 PM logo20 Biggest Losers on NASDAQ Trading (NASDAQ:ARIA) - October 17 at 8:23 AM
News IconInvestor News: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) faces Investigation over potential Violations of Securities Laws (NASDAQ:ARIA) - October 17 at 8:23 AM
News IconStocks to Must have in Portfolio: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), ACADIA Pharmaceuticals Inc. (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:ARIA) - October 15 at 3:31 PM logoWhy Ariad Pharmaceuticals, Infosys, and Natural Health Trends ... - Motley Fool (NASDAQ:ARIA) - October 15 at 3:31 PM logoWhy Ariad Pharmaceuticals Tumbled 14.8% Today - Motley Fool (NASDAQ:ARIA) - October 15 at 3:31 PM logoCowen Lifts Price Target on Ariad Pharmaceuticals, Inc. (ARIA) Amid Promising Long-Term Prospects for Brigatinib (NASDAQ:ARIA) - October 15 at 8:24 AM
News IconSanders Tweet Wipes $387M From Firm's Value (NASDAQ:ARIA) - October 15 at 8:24 AM logoSanders’ Tweet on Drugmaker Ariad’s ‘Greed’ Sends Stock Plunging (NASDAQ:ARIA) - October 15 at 8:24 AM logoBernie Sanders Tweet Causes Ariad Pharma Stock to Plunge 14% (NASDAQ:ARIA) - October 15 at 8:24 AM


Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Thursday, October, 27, 2016

Last Updated on 10/27/2016 by Staff